DNTH – dianthus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at HC Wainwright from $40.00 to $47.00. They now have a "buy" rating on the stock.
Assessing Dianthus Therapeutics (DNTH) Valuation Following Strong Revenue Growth and Recent Share Price Momentum [Yahoo! Finance]
Dianthus Therapeutics (NASDAQ:DNTH) had its price target raised by analysts at Wedbush from $44.00 to $46.00. They now have an "outperform" rating on the stock.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan
Form SCHEDULE 13D/A Dianthus Therapeutics, Filed by: Fairmount Funds Management LLC
Form SCHEDULE 13D/A Dianthus Therapeutics, Filed by: Avidity Partners Management LP
Form 4 Dianthus Therapeutics, For: Nov 13 Filed by: Randhawa Simrat
Form SCHEDULE 13G/A Dianthus Therapeutics, Filed by: Octagon Capital Advisors LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.